Physician profile
Mary Kwee
NPI 1275913840
$3,085.74
in general payments reported to CMS, 2019-2025
21 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $186 · 2024: $1,214 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,054 · Education: $31.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,054.24 |
| Education | $31.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $392.58 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Amgen INC. | $359.96 | 2023-2025 | Repatha, Repatha |
| Medtronic, INC. | $290.43 | 2023-2024 | Micra, Aurora Ev-Icd Mri Surescan, Linq II |
| Novartis Pharmaceuticals Corporation | $273.25 | 2024-2025 | |
| Scpharmaceuticals INC. | $248.85 | 2023-2025 | |
| Pfizer INC. | $222.50 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $201.61 | 2024-2025 | Camzyos, Eliquis |
| Bridgebio Pharma, INC. | $176.23 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $157.15 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $153.01 | 2023-2024 | Farxiga, Lokelma |
| Actelion Pharmaceuticals US, INC. | $139.04 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Merck Sharp & Dohme LLC | $119.69 | 2024-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $118.31 | 2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $50.17 | 2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $39.04 | 2024-2025 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $37.64 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Boston Scientific Corporation | $37.15 | 2024 | Latitude Communicator Power Supply |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.58 | 2025 | Lifevest |
| Altathera Pharmaceuticals LLC | $17.07 | 2025 | Sotalol Hydrochloride |
| Lexicon Pharmaceuticals, INC. | $16.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.48 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Kwee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.